A Phase 2 interventional study of Placebo and Pegfilgrastim in Colon Cancer, Colorectal Cancer and Rectal Cancer, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-17.
Sponsored by Amgen · Phase 2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Colonic Neoplasms by Amgen — none open to participants now, none under way, none of them phase 3. Colonic Neoplasms · Amgen.
Among the 15 studies in Colonic Neoplasms by Amgen, this one is the 5th largest by enrollment, is the only one that started in 2003, is one of 9 in phase 2, and was the 2nd registered.
2,456 studies on the registry are indexed under Colonic Neoplasms; 457 are open to participants now.
Browse Colonic Neoplasms studies →None of the 15 studies in Colonic Neoplasms by Amgen is open now. The open studies under Colonic Neoplasms, anywhere →
Of the 327 Colonic Neoplasms studies recruiting now, 203 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 3
First in 2002; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 252 is above the median of 75 across 1,710 interventional studies indexed under Colonic Neoplasms.
Median enrollment 150 across the 15 interventional studies. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Colonic Neoplasms by Amgen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to evaluate the safety and effectiveness of pegfilgrastim in reducing grade 3/4 neutropenia when given after one of three chemotherapy regimens (FOIL, FOLFOX or FOLFIRI) in patients with locally advanced or metastatic colorectal cancer. This study is considered to be "investigational" because the time between receiving pegfilgrastim and the next cycle of chemotherapy is only 11 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6 mg pegfilgrastim
Drug: Pegfilgrastim
6 mg placebo
Drug: Placebo
Subjects randomized to placebo will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
Subjects randomized to pegfilgrastim will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
Grade 3 or 4 Neutropenia
Grade 3 or 4 neutropenia, defined as an absolute neutrophil count (ANC) \< 1 x 10\^9/L, in any of the first four cycles of treatment
Time frame: First 4 cycles of treatment (8 weeks)
Grade 4 Neutropenia
Grade 4 neutropenia, defined as an absolute neutrophil count (ANC) \<0.5 x 10\^9/L, in any of the first four cycles of treatment
Time frame: First 4 cycles of treatment (8 weeks)
Dose Delay or Reduction Due to Neutropenia
Dose delay or reduction in chemotherapy doses due to neutropenia
Time frame: First 4 cycles of treatment (8 weeks)
Dose Delay or Reduction for Any Reason
Dose delay or reduction in chemotherapy dose during the first 4 cycles for any reason
Time frame: First 4 cycles of treatment (8 weeks)
Febrile Neutropenia
Febrile neutropenia, Defined as a temperature ≥ 38.2 °C on a given day, with an ANC \< 1.0 x 10\^9/L recorded on the same day or the next day, during any of the first 4 cycles of treatment.
Time frame: First 4 cycles of treatment (8 weeks)
Hospitalization Due to a Neutropenia-Related Event
Hospitalization because of a neutropenia-related event during the first 4 cycles of treatment
Time frame: First 4 cycles of neutropenia (8 weeks)
Progression-Free Survival
Kaplan-Meier estimate of the median time to disease progression or death
Time frame: Up to 24 months after first four cycles of treatment
Objective Tumor Response
Objective tumor response (complete or partial) at the end of treatment, defined as a reduction of at least 50% in the area of all measurable lesions (partial response) or disappearance of all measurable or evaluable disease without the development of new lesions (complete response) on computed tomographic (CT) or other scanning.
Time frame: First 4 cycles of treatment (8 weeks)
Survival
Death from any cause through the end of the follow-up period
Time frame: Up to 24 months after first four cycles of treatment
Antibiotic Use Due to Febrile Neutropenia
Antibiotic use during any of the first 4 cycles of treatment due to febrile neutropenia.
Time frame: First 4 cycles of treatment (8 weeks)
Participants were enrolled from 12 February 2003 through 13 January 2006
| Milestone | Pegfilgrastim (Neulasta) | Placebo |
|---|---|---|
| Started | 126 | 126 |
| Received study drug | 124 | 118 |
| Properly consented; received study drug | 123 | 118 |
| Completed all 4 cycles of treatment | 98 | 90 |
| Completed | 74 | 61 |
| Not completed | 52 | 65 |
| Withdrew: Protocol deviation | 2 | 2 |
| Withdrew: Noncompliance | 1 | 0 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Withdrawal by subject | 8 | 9 |
| Withdrew: Disease progression | 3 | 3 |
| Withdrew: Physician decision | 3 | 5 |
| Withdrew: Lost to follow-up | 6 | 6 |
| Withdrew: Death | 19 | 25 |
| Withdrew: Protocol-specified criteria | 1 | 1 |
| Withdrew: Other | 2 | 4 |
| Withdrew: Informed consent signed after treatment | 1 | 0 |
| Withdrew: Study drug not received | 2 | 8 |
| Withdrew: Other | 1 | 1 |
Grade 3 or 4 neutropenia, defined as an absolute neutrophil count (ANC) \< 1 x 10\^9/L, in any of the first four cycles of treatment
| Participants | Pegfilgrastim (Neulasta) | Placebo |
|---|---|---|
| Grade 3 or 4 Neutropenia | 16 | 51 |
Dose delay or reduction in chemotherapy doses due to neutropenia
| Participants | Pegfilgrastim (Neulasta) | Placebo |
|---|---|---|
| Dose Delay or Reduction Due to Neutropenia | 5 | 26 |
Dose delay or reduction in chemotherapy dose during the first 4 cycles for any reason
| Participants | Pegfilgrastim (Neulasta) | Placebo |
|---|---|---|
| Dose Delay or Reduction for Any Reason | 41 | 53 |
Febrile neutropenia, Defined as a temperature ≥ 38.2 °C on a given day, with an ANC \< 1.0 x 10\^9/L recorded on the same day or the next day, during any of the first 4 cycles of treatment.
| Participants | Pegfilgrastim (Neulasta) | Placebo |
|---|---|---|
| Febrile Neutropenia | 3 | 10 |
Hospitalization because of a neutropenia-related event during the first 4 cycles of treatment
| Participants | Pegfilgrastim (Neulasta) | Placebo |
|---|---|---|
| Hospitalization Due to a Neutropenia-Related Event | 7 | 9 |
Kaplan-Meier estimate of the median time to disease progression or death
| Days | Pegfilgrastim (Neulasta) | Placebo |
|---|---|---|
| Progression-Free Survival | 318 (258 to 387) | 322 (268 to 387) |
Objective tumor response (complete or partial) at the end of treatment, defined as a reduction of at least 50% in the area of all measurable lesions (partial response) or disappearance of all measurable or evaluable disease without the development of new lesions (complete response) on computed tomographic (CT) or other scanning.
| Participants | Pegfilgrastim (Neulasta) | Placebo |
|---|---|---|
| Objective Tumor Response | 34 | 37 |
Death from any cause through the end of the follow-up period
| Participants | Pegfilgrastim (Neulasta) | Placebo |
|---|---|---|
| Survival | 47 | 49 |
Antibiotic use during any of the first 4 cycles of treatment due to febrile neutropenia.
| Participants | Pegfilgrastim (Neulasta) | Placebo |
|---|---|---|
| Antibiotic Use Due to Febrile Neutropenia | 2 | 8 |
Grade 4 neutropenia, defined as an absolute neutrophil count (ANC) \<0.5 x 10\^9/L, in any of the first four cycles of treatment
| Participants | Pegfilgrastim (Neulasta) | Placebo |
|---|---|---|
| Grade 4 Neutropenia | 13 | 17 |
Collected over During treatment period and including 30 days after last dose of IP. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 36/117 (30.8%) | 108/117 (92.3%) |
| Pegfilgrastim | — | 44/124 (35.5%) | 112/124 (90.3%) |
| Event | Placebo | Pegfilgrastim |
|---|---|---|
| DehydrationMetabolism and nutrition disorders | 6/117 | 14/124 |
| NauseaGastrointestinal disorders | 7/117 | 2/124 |
| NeutropeniaBlood and lymphatic system disorders | 2/117 | 7/124 |
| DiarrhoeaGastrointestinal disorders | 3/117 | 7/124 |
| Febrile neutropeniaBlood and lymphatic system disorders | 6/117 | 3/124 |
| VomitingGastrointestinal disorders | 6/117 | 2/124 |
| PneumoniaInfections and infestations | 2/117 | 5/124 |
| Abdominal painGastrointestinal disorders | 3/117 | 1/124 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 3/117 | 2/124 |
| Deep vein thrombosisVascular disorders | 3/117 | 1/124 |
| Event | Placebo | Pegfilgrastim |
|---|---|---|
| NauseaGastrointestinal disorders | 53/117 | 69/124 |
| DiarrhoeaGastrointestinal disorders | 53/117 | 62/124 |
| NeutropeniaBlood and lymphatic system disorders | 55/117 | 11/124 |
| FatigueGeneral disorders | 44/117 | 49/124 |
| AnaemiaBlood and lymphatic system disorders | 32/117 | 36/124 |
| VomitingGastrointestinal disorders | 22/117 | 35/124 |
| AnorexiaMetabolism and nutrition disorders | 14/117 | 29/124 |
| Abdominal painGastrointestinal disorders | 16/117 | 22/124 |
| AstheniaGeneral disorders | 6/117 | 22/124 |
| Weight decreasedInvestigations | 8/117 | 19/124 |
| Age, Continuous(Years) | Pegfilgrastim (Neulasta) | Placebo | Total |
|---|---|---|---|
| Mean | 62.4 ± 12.26 | 62.9 ± 13.21 | 62.7 ± 12.71 |
| Sex: Female, Male(Participants) | Pegfilgrastim (Neulasta) | Placebo | Total |
|---|---|---|---|
| Female | 45 | 34 | 79 |
| Male | 78 | 84 | 162 |
| Race/Ethnicity, Customized(Participants) | Pegfilgrastim (Neulasta) | Placebo | Total |
|---|---|---|---|
| White or Caucasian | 103 | 84 | 187 |
| Black or African American | 12 | 12 | 24 |
| Hispanic or Latino | 3 | 16 | 19 |
| Asian | 3 | 3 | 6 |
| Japanese | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 3 | 3 |
| Other | 1 | 0 | 1 |
| Chemotherapy Regimen(Participants) | Pegfilgrastim (Neulasta) | Placebo | Total |
|---|---|---|---|
| FOIL | 30 | 30 | 60 |
| FOLFOX | 61 | 58 | 119 |
| FOLFIRI | 32 | 30 | 62 |
No study locations are listed for this record.
Ran from Feb 2003 to primary completion in May 2006, 39 months.
Results were first posted in Jan 2011, 4 years 7 months after primary completion.
Of 136 phase 2 interventional studies under Colonic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 39 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegfilgrastim